These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 19299892)

  • 1. Interaction of aldosterone and extracellular volume in the pathogenesis of obesity-associated kidney disease: a narrative review.
    Bomback AS; Klemmer PJ
    Am J Nephrol; 2009; 30(2):140-6. PubMed ID: 19299892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension.
    Whaley-Connell A; Johnson MS; Sowers JR
    Prog Cardiovasc Dis; 2010; 52(5):401-9. PubMed ID: 20226958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension.
    Sowers JR; Whaley-Connell A; Epstein M
    Ann Intern Med; 2009 Jun; 150(11):776-83. PubMed ID: 19487712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obesity and kidney disease: from population to basic science and the search for new therapeutic targets.
    Whaley-Connell A; Sowers JR
    Kidney Int; 2017 Aug; 92(2):313-323. PubMed ID: 28341271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of aldosterone in cardiovascular disease in people with diabetes and hypertension: an update.
    Lastra-Gonzalez G; Manrique-Acevedo C; Sowers JR
    Curr Diab Rep; 2008 Jun; 8(3):203-7. PubMed ID: 18625117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease: Efficacy and Safety.
    Bomback AS
    Blood Purif; 2016; 41(1-3):166-70. PubMed ID: 26765793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mineralocorticoid Receptor Blockade in End-Stage Renal Disease.
    Lyubarova R; Gosmanova EO
    Curr Hypertens Rep; 2017 May; 19(5):40. PubMed ID: 28451852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients.
    Gross E; Rothstein M; Dombek S; Juknis HI
    Am J Kidney Dis; 2005 Jul; 46(1):94-101. PubMed ID: 15983962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reviving the use of aldosterone inhibitors in treating hypertension in obesity.
    Huby AC; Belin De Chantemèle EJ
    Am J Physiol Regul Integr Comp Physiol; 2015 Nov; 309(9):R1065-7. PubMed ID: 26157057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological strategies for kidney function preservation: are there differences by ethnicity?
    Lakkis J; Weir MR
    Adv Ren Replace Ther; 2004 Jan; 11(1):24-40. PubMed ID: 14730536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin-angiotensin-aldosterone system among patients with obesity and proteinuria.
    Morales E; Gutiérrez E; Caro J; Sevillano A; Rojas-Rivera J; Praga M
    Nefrologia; 2015; 35(6):554-61. PubMed ID: 26519114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A critical review of the evidence supporting aldosterone in the etiology and its blockade in the treatment of obesity-associated hypertension.
    Byrd JB; Brook RD
    J Hum Hypertens; 2014 Jan; 28(1):3-9. PubMed ID: 23698003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aldosterone blockade in chronic kidney disease.
    Hirsch JS; Drexler Y; Bomback AS
    Semin Nephrol; 2014 May; 34(3):307-22. PubMed ID: 25016401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New roles of aldosterone and mineralocorticoid receptors in cardiovascular disease: translational and sex-specific effects.
    Davel AP; Jaffe IZ; Tostes RC; Jaisser F; Belin de Chantemèle EJ
    Am J Physiol Heart Circ Physiol; 2018 Oct; 315(4):H989-H999. PubMed ID: 29957022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mineralocorticoid receptor activation in obesity hypertension.
    Nagase M; Fujita T
    Hypertens Res; 2009 Aug; 32(8):649-57. PubMed ID: 19521418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obesity, sleep apnea, aldosterone, and hypertension.
    Goodfriend TL
    Curr Hypertens Rep; 2008 Jun; 10(3):222-6. PubMed ID: 18765094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aldosterone blockade: the heart versus the kidney.
    Bhandari S
    Kidney Int; 2012 Nov; 82(10):1136; author reply 1136-7. PubMed ID: 23128119
    [No Abstract]   [Full Text] [Related]  

  • 18. Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms.
    Shavit L; Lifschitz MD; Epstein M
    Kidney Int; 2012 May; 81(10):955-968. PubMed ID: 22336987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldosterone's impact on kidney health: exploring the benefits of mineralocorticoid receptor antagonists for renal protection.
    Liu Z; Xie B; Pang S; Xie Y; Jili M; Mo Z; Li W; Yang R
    Am J Transl Res; 2024; 16(8):4246-4255. PubMed ID: 39262744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mineralocorticoid-induced sodium appetite and renal salt retention: evidence for common signaling and effector mechanisms.
    Fu Y; Vallon V
    Nephron Physiol; 2014; 128(1-2):8-16. PubMed ID: 25376899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.